CG Oncology, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
CGON$72.64-2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating Activities | ||
| Net loss | $(196,149) | $(119,686) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,846 | 596 |
| Stock-based compensation expense | 29,264 | 19,489 |
| Unrealized losses (gains) on short-term investments | 9,949 | (1,965) |
| Non-cash interest expense (income) | 139 | (844) |
| Non-cash lease expense | 101 | 21 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (6,374) | (90) |
| Accounts receivable, net | 22 | (19) |
| Inventory | 400 | (380) |
| Other assets | (5,668) | (20) |
| Accounts payable | 4,058 | 1,835 |
| Accrued expenses and other current liabilities | 11,326 | 4,924 |
| Other liabilities | (978) | 9 |
| Net cash used in operating activities | (151,064) | (96,130) |
| Investing Activities | ||
| Proceeds from sales and maturities of investments | 649,450 | 621,899 |
| Purchases of investments | (905,945) | (770,122) |
| Acquisition, net of cash acquired | — | (21,967) |
| Purchases of property and equipment | (1,887) | (127) |
| Net cash used in investing activities | (258,382) | (170,317) |
| Financing Activities | ||
| Proceeds from follow-on public offerings, net of issuance costs | 391,550 | 49,001 |
| Proceeds from exercise of common stock options | 14,036 | 5,800 |
| Withholding taxes paid on net exercise of stock options | (197) | — |
| Stock issuance costs | (186) | (277) |
| Net cash provided by financing activities | 405,203 | 54,524 |
| Net decrease in cash and cash equivalents | (4,243) | (211,923) |
| Cash and cash equivalents at beginning of period | 32,490 | 257,068 |
| Cash and cash equivalents at end of period | $28,247 | $45,145 |
| Supplemental Disclosure of Cash Flow Information | ||
| Cash paid for interest | $142 | $— |
| Cash paid for taxes | $14 | $16 |
| Non-cash Investing and Financing Activities: | ||
| Operating lease right-of-use asset obtained in exchange for lease liabilities | $3,483 | $859 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.